Your Partner in Innovative Cancer Care

Together with you – the healthcare professional in practice or training – we’re finding the answers, insights, and treatment options that people with cancer deserve.

How to Refer a Patient

Memorial Sloan Kettering’s Patient Access Service is an easy way for doctors to refer a patient to a Memorial Sloan Kettering specialist. Find helpful phone numbers and other resources.

Learn more


Our renowned fellowship programs prepare doctors for leadership roles in the care of people with cancer around the world.

Clinical Trials

At any one time Memorial Sloan Kettering is running hundreds of clinical trials. Through these studies we can improve care for people with all types of cancer. Browse the MSK clinical trials that are currently enrolling new patients.

View all clinical trials
Prediction Tools

MSK’s researchers have developed prediction tools known as nomograms. These tests can help people with cancer and doctors make treatment decisions. The tools can be used to predict cancer outcomes. Nomograms also assess an individual’s risk based on the characteristics of their specific disease.

View all nomograms
Clinical Updates & Insights

Get the latest updates from MSK doctors. Read about new treatments, clinical trials, and innovations in detecting and treating many cancers.

Browse clinical updates

Clinical Update

New Imaging Method Can Diagnose and Direct Treatment of Rare Pediatric Retinoblastoma

Decreasing values for apparent diffusion coefficient (ADC) mapping derived from MRI may indicate the development of trilateral retinoblastoma in pediatric patients with bilateral retinoblastoma.

Clinical Update

New Molecular Signatures of High-Risk Neuroblastoma

High-risk neuroblastoma cells harbor distinguishing molecular signatures, according to recent research.

Clinical Update

Hepatic Arterial Infusion Converts “Unresectable” Colorectal Liver Mets

The advent of hepatic arterial infusion chemotherapy (HAI) for treating patients with resectable colorectal liver metastases has increased survival outcomes to previously unimaginable levels. However, questions remain about the effectiveness of its use in patients with initially unresectable colorectal liver metastases.